JP2011505341A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505341A5
JP2011505341A5 JP2010535064A JP2010535064A JP2011505341A5 JP 2011505341 A5 JP2011505341 A5 JP 2011505341A5 JP 2010535064 A JP2010535064 A JP 2010535064A JP 2010535064 A JP2010535064 A JP 2010535064A JP 2011505341 A5 JP2011505341 A5 JP 2011505341A5
Authority
JP
Japan
Prior art keywords
group
nhc
alkyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010535064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/084193 external-priority patent/WO2009067600A2/en
Publication of JP2011505341A publication Critical patent/JP2011505341A/ja
Publication of JP2011505341A5 publication Critical patent/JP2011505341A5/ja
Pending legal-status Critical Current

Links

JP2010535064A 2007-11-21 2008-11-20 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤 Pending JP2011505341A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98955107P 2007-11-21 2007-11-21
PCT/US2008/084193 WO2009067600A2 (en) 2007-11-21 2008-11-20 Biaryl pde4 inhibitors for treating inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014046962A Division JP2014185149A (ja) 2007-11-21 2014-03-10 炎症を治療するためのビアリールｐｄｅ４阻害薬

Publications (2)

Publication Number Publication Date
JP2011505341A JP2011505341A (ja) 2011-02-24
JP2011505341A5 true JP2011505341A5 (enExample) 2013-03-14

Family

ID=41650335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535064A Pending JP2011505341A (ja) 2007-11-21 2008-11-20 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤

Country Status (6)

Country Link
EP (1) EP2222638A2 (enExample)
JP (1) JP2011505341A (enExample)
CN (1) CN102089279A (enExample)
AU (1) AU2008326381B2 (enExample)
CA (1) CA2722582A1 (enExample)
WO (1) WO2009067600A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829713B2 (en) 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
WO2010059838A2 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
JP2013532734A (ja) * 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
CA2819299A1 (en) * 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN103012255B (zh) * 2011-09-21 2014-06-11 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
CN102603676B (zh) * 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
CN103012408B (zh) * 2012-11-28 2015-02-04 中国科学院广州生物医药与健康研究院 依匹斯汀的合成方法
AU2014241430B2 (en) * 2013-03-14 2018-04-26 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
US9790223B2 (en) 2014-03-14 2017-10-17 Wockhardt Limited Process for preparation of sodium (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
RU2741576C2 (ru) 2014-10-24 2021-01-27 Лэндос Байофарма, Инк. Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US11197891B2 (en) 2017-11-30 2021-12-14 Landos Biopharma, Inc. Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
KR102666727B1 (ko) 2017-12-29 2024-05-21 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도
CN110041253B (zh) * 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
JP2022531129A (ja) * 2019-04-23 2022-07-06 テトラ ディスカバリー パートナーズ インコーポレイテッド Ｐｄｅ４ｄ阻害剤としての３－ヒドロキシ－２－フェニル－６－（ピラゾール－４－イルメチル）ピリジン誘導体
AU2020407645B2 (en) 2019-12-20 2022-10-06 Nimmune Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
CN113912593A (zh) * 2020-07-10 2022-01-11 启元生物(杭州)有限公司 一种氘代吡啶酮类化合物及其应用
US20240101552A1 (en) 2020-09-18 2024-03-28 Shanghai Pharmaceuticals Holding Co., Ltd. Carbonyl heterocyclic compound and application thereof
CN112374984A (zh) * 2020-11-06 2021-02-19 苏州求索生物科技有限公司 一种2-溴-4-羟基苯甲醚的制备工艺
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
CN117756794B (zh) * 2023-12-18 2024-07-16 和径医药科技（上海）有限公司 一种含氮杂环类化合物及其制备方法和应用
WO2025240840A1 (en) * 2024-05-17 2025-11-20 Shionogi & Co., Ltd. Aromatic heterocycle derivatives and aromatic carbocycle derivatives having pde4d inhibitory activity
CN118994115B (zh) * 2024-07-29 2025-09-09 宁波大学 治疗甲基苯丙胺成瘾及认知障碍的新化合物制备和应用
CN119819277B (zh) * 2025-03-17 2025-05-27 昆明医科大学 一种基于BINAM的β-环糊精衍生物手性固定相及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249963B1 (en) * 1986-06-20 1992-04-22 Idemitsu Kosan Company Limited Polycarbonates
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
WO1996016058A1 (en) * 1994-11-23 1996-05-30 Neurogen Corporation Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
FR2754260B1 (fr) * 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU1504599A (en) * 1997-12-17 1999-07-05 Shionogi & Co., Ltd. Novel pyridine compounds
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
WO2000014083A1 (en) * 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
US6518257B1 (en) * 1999-10-22 2003-02-11 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004084824A2 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
CA2520804A1 (en) * 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
US7557143B2 (en) * 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7456218B2 (en) * 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
AP2007003980A0 (en) * 2004-11-23 2007-06-30 Pfizer Prod Inc Dibenzylamine compounds and derivatives
KR101316992B1 (ko) * 2004-12-23 2013-10-11 갈데르마 리써어치 앤드 디벨로프먼트 Ｒａｒ 수용체를 조절하는 신규 리간드, 및 인간 의학 및화장품에서의 그의 용도
WO2006083477A2 (en) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
PT2404919E (pt) * 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP2016065B1 (en) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
JP5040036B2 (ja) * 2005-12-30 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CN101506158A (zh) * 2006-06-28 2009-08-12 株式会社三和化学研究所 新6-5系二环式杂环衍生物及其医药用途
US8633175B2 (en) * 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
US20100249084A1 (en) * 2007-03-21 2010-09-30 Youngsheng Chen Substituted pyrimidines as adenosine receptor antagonists
CN103351390A (zh) * 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
FR2932180B1 (fr) * 2008-06-04 2012-08-10 Centre Nat Rech Scient Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline

Similar Documents

Publication Publication Date Title
JP2011504505A5 (enExample)
AU663149B2 (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
RU2573834C2 (ru) ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
AU2008326309C1 (en) Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
Abdelazeem et al. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile
JP2018519323A5 (enExample)
BG106678A (bg) ПИРАЗОЛО [4,3 - d] ПИРИМИДИНОВИ ПРОИЗВОДНИ
JP2007510689A (ja) 新規ピリダジン−３（２ｈ）−オン誘導体
EP2222638A2 (en) Biaryl pde4 inhibitors for treating inflammation
KR20180032645A (ko) Ror 감마 조절제로서의 신규한 화합물
JP2011504183A5 (enExample)
JP2012188363A (ja) アザベンゾイミダゾロン誘導体
JP2002088073A (ja) 抗アンドロゲン剤
JP2005533805A (ja) 新規化合物
TW201609707A (zh) 新穎之經取代嘧啶化合物
WO2012028106A1 (en) Deuterium-enriched heterocyclic compounds as kinase inhibitors
CA2793709A1 (en) Therapeutic agent or prophylactic agent for fibromyalgia
JP2006528624A (ja) Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体
JP2008520644A (ja) オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
KR20150046456A (ko) 신규한 항진균성 옥소다이하이드로피리딘카보하이드라자이드 유도체
HK40070781A (en) Process for making deuterated hydroxy-benzbromarone and intermediates thereof
WO2025147670A1 (en) Lysine acetyltransferase inhibitors
HK40070781B (en) Process for making deuterated hydroxy-benzbromarone and intermediates thereof
KR101646180B1 (ko) N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제